Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly; DRG forecasts PD prevalence to grow 2% annually in the major pharmaceutical markets through 2025. The market for PD pharmacotherapies features a high rate of polypharmacy that is unique among neurological disorders, driven by the need to simultaneously manage the primary motor symptoms and associated nonmotor symptoms of the disease, as well as the common complications associated with chronic treatment with levodopa (Merck/Bristol-Myers Squibb/DuPont Pharma’s Sinemet, Sinemet CR, other brands, generics), the long-standing foundation of PD treatment. A growing population, high diagnosis and drug-treatment rates, a high rate of polypharmacy, a complex symptomology, and several key areas of unmet need combine to make the PD market a significant commercial opportunity for therapeutic advances. Based on the active and diverse late-stage pipeline—which includes innovative reformulations, novel adjuncts to levodopa, and new and improved rescue therapies—we forecast continued growth of the PD pharmaceutical market over the 2015-2025 forecast period. 

 


Related Reports

Parkinson's Disease - Landscape & Forecast - Disease Landscape & Forecast

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more a...

View Details

Parkinson's Disease - Unmet Need - Detailed, Expanded Analysis: Psychosis In PD (US/FR/DEU/UK)

Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD patie...

View Details

Parkinson's Disease | Disease Landscape and Forecast | G7 | 2019

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two new re...

View Details